CARB-X is a non-profit partnership
CARB-X, led by Boston University, is funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) in the United States Department of Health and Human Services, the Wellcome Trust in the United Kingdom, and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The UK Government’s Department of Health and Social Care (DHSC), through its Global Antimicrobial Resistance Innovation Fund (GAMRIF) has been a CARB-X funding partner since May 2018. The Bill and Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world, is a CARB-X Alliance Partner since May 2018. Germany’s Federal Ministry of Education and Research (BMBF) has been a funding partner since March 2019. With funds from its Funding and Alliance Partners, CARB-X is investing more than US$500 million from 2016-2021 to accelerate the development of innovative antibiotics and other therapeutics, vaccines, and rapid diagnostics to address drug-resistant bacterial infections.
Business, technical and scientific support for CARB-X-funded product developers is provided in partnership with CARB-X’s Global Accelerator Network.